Patents by Inventor Herbert Y. Lin

Herbert Y. Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR REGULATING IRON HOMEOSTASIS BY MODULATION OF BMP-6
    Publication number: 20210388069
    Abstract: Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.
    Type: Application
    Filed: January 19, 2021
    Publication date: December 16, 2021
    Inventors: Herbert Y. Lin, Jodie Babitt
  • Nucleic acids encoding hemojuvelin fusion proteins and uses thereof
    Patent number: 10611820
    Abstract: The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also provided are methods for treating iron-related disorders which include administration of a HJV fusion protein to a patient in need thereof.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: April 7, 2020
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Herbert Y. Lin, Jodie Babitt, Clifford J. Woolf, Tarek A. Samad
  • Compositions for regulating iron homeostasis and methods of using same
    Patent number: 10273273
    Abstract: The present invention relates to hemojuvelin-IgG Fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: April 30, 2019
    Assignees: THE GENERAL HOSPITAL CORPORATION, FERRUMAX CORPORATION
    Inventors: Herbert Y. Lin, Jodie L. Babitt, Tracey Menhall, Patrick Gearing
  • Hemojuvelin Fusion Proteins And Uses Thereof
    Publication number: 20180072790
    Abstract: The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins.
    Type: Application
    Filed: August 21, 2017
    Publication date: March 15, 2018
    Inventors: Herbert Y. Lin, Jodie Babitt, Clifford J. Woolf, Tarek A. Samad
  • Compositions for Regulating Iron Homeostasis and Methods of Using Same
    Publication number: 20180044389
    Abstract: The present invention relates to hemojuvelin-IgG Fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis.
    Type: Application
    Filed: July 17, 2017
    Publication date: February 15, 2018
    Inventors: Herbert Y. Lin, Jodie L. Babitt, Tracey Menhall, Patrick Gearing
  • METHODS AND COMPOSITIONS FOR REGULATING IRON HOMEOSTASIS BY MODULATION OF BMP-6
    Publication number: 20170362311
    Abstract: Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of hemochromatosis and anemia of inflammation.
    Type: Application
    Filed: May 18, 2017
    Publication date: December 21, 2017
    Inventors: Herbert Y. Lin, Jodie Babitt
  • Hemojuvelin fusion proteins and uses thereof
    Patent number: 9758567
    Abstract: The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also provided are methods for treating iron-related disorders which include administration of a HJV fusion protein to a patient in need thereof.
    Type: Grant
    Filed: October 20, 2014
    Date of Patent: September 12, 2017
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Herbert Y. Lin, Jodie Babitt, Clifford J. Woolf, Tarek A. Samad
  • Compositions for regulating iron homeostasis and methods of using same
    Patent number: 9708379
    Abstract: The present disclosure relates to hemojuvelin-IgG Fc domain fusion proteins, variants, derivatives, fragments and peptide mimetics derived therefrom and methods of using these fusion proteins for the regulation of iron homeostasis and the treatment of diseases related to iron homeostasis.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: July 18, 2017
    Assignees: THE GENERAL HOSPITAL CORPORATION, FERRUMAX CORPORATION
    Inventors: Herbert Y. Lin, Jodie L. Babitt, Tracey Menhall, Patrick Gearing
  • METHODS AND COMPOSITIONS TO REGULATE HEPCIDIN EXPRESSION
    Publication number: 20170183411
    Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.
    Type: Application
    Filed: December 12, 2016
    Publication date: June 29, 2017
    Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
  • Methods and compositions to regulate hepcidin expression
    Patent number: 9556251
    Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: January 31, 2017
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
  • Compositions and methods for inhibiting expression of the HAMP gene
    Patent number: 9506067
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: November 29, 2016
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Tomoko Nakayama, Anke Geick, Pamela Tan, Herbert Y. Lin
  • Compositions And Methods For Inhibiting Expression Of The HAMP Gene
    Publication number: 20160102312
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.
    Type: Application
    Filed: June 19, 2015
    Publication date: April 14, 2016
    Inventors: Tomoko Nakayama, Anke Geick, Pamela Tan, Herbert Y. Lin
  • Compositions and methods for inhibiting expression of the HAMP gene
    Patent number: 9090895
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.
    Type: Grant
    Filed: June 13, 2014
    Date of Patent: July 28, 2015
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Tomoko Nakayama, Anke Geick, Pamela Tan, Herbert Y. Lin
  • HEMOJUVELIN FUSION PROTEINS AND USES THEREOF
    Publication number: 20150139993
    Abstract: The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also provided are methods for treating iron-related disorders which include administration of a HJV fusion protein to a patient in need thereof.
    Type: Application
    Filed: October 20, 2014
    Publication date: May 21, 2015
    Inventors: Herbert Y. Lin, Jodie Babitt, Clifford J. Woolf, Tarek A. Samad
  • METHODS AND COMPOSITIONS TO REGULATE HEPCIDIN EXPRESSION
    Publication number: 20150072927
    Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.
    Type: Application
    Filed: July 16, 2014
    Publication date: March 12, 2015
    Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
  • Hemojuvelin fusion proteins and uses thereof
    Patent number: 8895002
    Abstract: The present invention provides a hemojuvelin (HJV) fusion protein (e.g., a human HJV.Fc) protein, polynucleotides and vectors encoding such proteins, and methods for making such proteins. Also provided are methods for treating iron-related disorders which include administration of a HJV fusion protein to a patient in need thereof.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: November 25, 2014
    Assignee: The General Hospital Corporation
    Inventors: Herbert Y. Lin, Jodie Babitt, Clifford J. Woolf, Tarek A. Samad
  • Methods and compositions to regulate hepcidin expression
    Patent number: 8865168
    Abstract: The present invention provides new systems and strategies for the regulation of iron metabolism in mammals. In particular, methods of using agonists and antagonists of TGF-? superfamily members to modulate the expression or activity of hepcidin, a key regulator of iron metabolism, are described. The inventive methods find applications in the treatment of diseases associated with iron overload, such as juvenile hemochromatosis and adult hemochromatosis, and in the treatment of diseases associated with iron deficiency, such as anemia of chronic disease and EPO resistant anemia in end-stage of renal disease. The present invention also relates to screening tools and methods for the development of novel drugs and therapies for treating iron metabolism disorders.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: October 21, 2014
    Assignee: The General Hospital Corporation
    Inventors: Herbert Y. Lin, Jodie Babitt, Raymond T. Chung, Tarek A. Samad, Alan L. Schneyer, Clifford J. Woolf
  • Compositions And Methods For Inhibiting Expression Of The HAMP Gene
    Publication number: 20140294936
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.
    Type: Application
    Filed: June 13, 2014
    Publication date: October 2, 2014
    Inventors: Tomoko Nakayama, Anke Geick, Pamela Tan, Herbert Y. Lin
  • Compositions and methods for inhibiting expression of the HAMP gene
    Patent number: 8791250
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition.
    Type: Grant
    Filed: May 23, 2013
    Date of Patent: July 29, 2014
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Tomoko Nakayama, Anke Geick, Pamela Tan, Herbert Y. Lin
  • METHODS AND COMPOSITIONS FOR REGULATING IRON HOMEOSTASIS BY MODULATION OF BMP-6
    Publication number: 20140199314
    Abstract: Modulation of iron homeostasis by regulating BMP-6 activity is provided. Methods of using BMP-6 and BMP-6 protein-specific reagents, such as antibodies, for altering serum iron levels in humans are provided. Such antibodies are useful in pharmaceutical compositions for the prevention and treatment of anemia and anemia of inflammation.
    Type: Application
    Filed: March 15, 2013
    Publication date: July 17, 2014
    Applicant: The General Hospital Corporation
    Inventors: Herbert Y. Lin, Jodie Babitt